P51 / Research station
Home / Research Library / Tesamorelin Research: GHRH Biology & Product Distinctions
Compound research profile

Tesamorelin Research: GHRH Biology & Product Distinctions

A research-focused introduction to tesamorelin, GHRH signaling, and the difference between approved product documentation and a research-material listing.

Peptides51 · Published October 9, 2026 · Source-linked educational overview

What is tesamorelin?

Tesamorelin is a growth-hormone-releasing hormone analog. The FDA prescribing information for EGRIFTA WR is a product-specific source for its pharmacology and regulated clinical context.

Why approved-product documentation is specific

The cited label applies to EGRIFTA WR, a particular formulation. Its existence does not mean an educational compound listing or a separately sourced research vial is approved, interchangeable, or manufactured to the same specifications.

Reading pharmacology and clinical evidence

Separate receptor and endocrine signaling questions from studies of a formulated medicine. Record the actual product, population, endpoints and study design instead of treating a shared compound name as proof of equivalence.

Comparing research-material documentation

Use batch documentation to assess the identity and analytical characteristics of a particular sample. A reference to prescribing information cannot replace those documents. This overview does not reproduce clinical instructions or recommend use.

Sources & further reading

  1. FDA — EGRIFTA WR prescribing information, 2025
This overview explains research context and evidence limits. It is not a systematic review or medical guidance. No availability, product quality, or equivalence to study materials is implied. Follow the original source for methods and limitations.

Continue reading

Explore all research guides →

Browse the compound directory →

P51 / Evidence tracker

FDA approval & clinical-trial status

Sources checked 2026-10-10 (UTC). Status describes registry records and named drug products.

FDA / United States

Approved prescription product records found

Drugs@FDA lists approved prescription products containing this ingredient. That approval belongs to the named drug products and their labeled indications; it does not approve Peptides51 research materials.

FDA database and coverage ↗
ClinicalTrials.gov

Active study records reported

3 active · 0 planned · 12 completed · 20 matching records

Counts include matching drug or biological interventions in ClinicalTrials.gov. Biomarker-only studies and related compounds are excluded. Registration and a reported phase do not establish safety, efficacy, FDA approval, or that a trial is taking place as described. Check each record and its update date.

Search the trial registry ↗
View matching trial records (20)
Publication archive

Articles associated with Tesamorelin

Indexed publications mentioning this compound in their title or abstract, newest first. Follow the original papers for findings and limitations; preprints are labeled.

Open full source search ↗

98 indexed matches. Sources checked 2026-10-10 (UTC).

Search coverage is limited to Europe PMC. Related names, formulations, and study models may differ from listed research materials. A paper mentioning a compound is not necessarily a clinical trial or evidence of effectiveness.